- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03033836
Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women (TRANSViiV)
Pilot Study of Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women
Prospective, open, single-arm trial of dolutegravir-tenofovir and emtricitabine or lamivudine (DTG-TDF-FTC or 3TC) in antiretroviral (ART) naïve HIV transgender women (TGW).
The primary objective of this pilot study is to determine the retention in care of TGW treated with DTG-TDF-FTC or 3TC
Secondary objectives:
- To evaluate the efficacy of the antiretroviral regimen at week 48 ;
- To describe the safety and tolerability of this regimen;
- To evaluate adherence across 48 weeks;
- To determine the patient satisfaction with this regimen;
- To identify individual, social and contextual factors associated with adherence and retention.
Panoramica dello studio
Descrizione dettagliata
The primary objective of this pilot study is to determine the retention in care of TGW treated with DTG-TDF-FTC.
The primary objective will be assessed by the proportion of individuals that provide information on ART use and virological outcomes at the end of the study:
- Retention under care: Proportion of enrolled and dosed individuals that provide clinical information up to 48 weeks of follow up.
- Retention on treatment: Proportion of enrolled and dosed individuals that receive study drugs up to 48 weeks of follow up.
Secondary objectives:
- To evaluate the efficacy of the antiretroviral regimen at week 48 ;
- To describe the safety and tolerability of this regimen;
- To evaluate adherence across 48 weeks;
- To determine the patient satisfaction with this regimen;
- To identify individual, social and contextual factors associated with adherence and retention.
The secondary objectives will be evaluated using the following endpoints:
- Proportion of patients with HIV-1 RNA levels of less than 50 copies/mL at 48 weeks of treatment by the IIT-exposed snapshot FDA algorithm;
- Frequency, type and severity of adverse events and laboratory abnormalities;
- Pill count, analogue visual scale for adherence in each visit;
- Changes in the scores of stigma and discrimination scales , quality of life, social support and anxiety and depression (BERGER, WBI,DUKE,CES-D,STAI) at bsl, 4,24, and 48 weeks e;.Changes in the score scales of sexual behaviors, use of drug /alcohol at bsl and at each visit .
f. Through association of baseline individual, social and contextual characteristics with percentage of adherence and retention at 48 weeks.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
Buenos Aires
-
Ciudad de Buenos Aires, Buenos Aires, Argentina, C1202ABB
- Fundacion Huesped
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- HIV-1 positive serology by at least two different serological tests (rapid test, ELISA, Western Blot) or a viral load higher than 3,000 copies/mL.
- 18 years and older.
- Self-identified as TGW
- ART naïve.
- Written informed consent provided.
Exclusion Criteria:
- Genotypic resistance to TDF and/or FTC as per IAS-USA resistance panel 2013.
- Alcohol or drug use that might affect adherence.
- Concomitant use of lipid-lowering drugs, interferon, interleukin-2, cytotoxic chemotherapy, dofetilide (or pilsicainide) or immunosuppressors, antacids drugs containing Ca++ and or Mg++ at study entry.
- Opportunistic infection (CDC "C" category) or other disease and/or clinical conditions that, in the investigator's opinion, would compromise the patient's safety or outcome of the study; including malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia.
- Treatment with any of the following agents within 28 days of screening: radiation therapy; cytotoxic chemotherapeutic agents; any immunomodulators that alter immune responses or treatment with an HIV-1 immunotherapeutic vaccine within 90 days of screening or exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of the investigational product.
- Contraindication to any of the study drugs (history of renal diseases, lab abnormalities grade 4 or any other clinical condition prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements).
- Anticipated need for Hepatitis C virus (HCV) therapy during the study.
- Creatinine clearance of <50 mL/min via Cockroft-Gault method.
- Subjects with moderate to severe hepatic impairment (Class B or greater) as determined by Child-Pugh classification.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: single arm
ARV treatment based on Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine
|
Dolutegravir 50 mg QD plus co-formulated emtricitabine 200 mg/tenofovir 300 mg QD.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Proportion of transgender women retained in care at week 48
Lasso di tempo: 48 weeks
|
Proportion of enrolled and dosed individuals that complete protocol defined visits during 48 weeks of follow up. Retention under care: Proportion of enrolled and dosed individuals that provide clinical information up to 48 weeks of follow up. Retention on treatment: Proportion of enrolled and dosed individuals that receive study drugs up to 48 weeks of follow up. |
48 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Proportion of individuals with HIV RNA undetectable at week 48
Lasso di tempo: 48 weeks
|
Proportion of patients with HIV-1 RNA levels less than 50 copies/mL at week 48 weeks of treatment by the IIT-exposed snapshot FDA algorithm;
|
48 weeks
|
Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality
Lasso di tempo: From baseline to week 48
|
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline.
The most severe graded abnormality from all tests was counted for each participant.
|
From baseline to week 48
|
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
Lasso di tempo: From baseline to week 48
|
Adverse events (AEs) occurring during treatment and for 30 days following the last dose of study drug were summarized across the participant population.
A participant was counted once if they had a qualifying event.
|
From baseline to week 48
|
Adherence using ACTG form
Lasso di tempo: From baseline to week 48
|
ACTG self report adherence form will be used for baseline and follow up visits
|
From baseline to week 48
|
Adherence using analogue visual scale
Lasso di tempo: From week 4 to week 48
|
Analogue visual scale (0-10) will be used at each follow up visit
|
From week 4 to week 48
|
Adherence by pill count
Lasso di tempo: From week 4 to week 48
|
Pill count of dispensed drugs
|
From week 4 to week 48
|
Quality of life by QoL Socre and Well being index
Lasso di tempo: From baseline to week 48
|
Changes in the scores of quality of life, will be done through Well-being Index questionnaire, this instrument will be administered to patients at baseline, week 4, 24 and week 48 .
|
From baseline to week 48
|
Patient´s satisfaction with this regimen
Lasso di tempo: From baseline to week 48
|
Changes in the scores of social support,will be done through Duke UNC questionnaire, this instrument will be administered to patients at baseline, week 4, 24 and week 48 .
|
From baseline to week 48
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Omar Sued, MD, PhMD, Fundacion Huesped
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Infezioni da virus a RNA
- Malattie virali
- Infezioni
- Infezioni a trasmissione ematica
- Malattie trasmissibili
- Malattie sessualmente trasmissibili, virali
- Malattie trasmesse sessualmente
- Infezioni da lentivirus
- Infezioni da retroviridae
- Sindromi da deficit immunologico
- Malattie del sistema immunitario
- Infezioni da HIV
- Meccanismi molecolari dell'azione farmacologica
- Agenti antinfettivi
- Agenti antivirali
- Inibitori della trascrittasi inversa
- Inibitori della sintesi degli acidi nucleici
- Inibitori enzimatici
- Agenti anti-HIV
- Agenti antiretrovirali
- Inibitori dell'integrasi dell'HIV
- Inibitori dell'integrasi
- Combinazione di farmaci Emtricitabina, Tenofovir disoproxil fumarato
- Dolutegravir
Altri numeri di identificazione dello studio
- FH-17
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Infezioni da HIV
-
University of MinnesotaRitiratoInfezioni da HIV | HIV/AIDS | HIV | AIDS | Problema di Aids/Hiv | AIDS e infezioniStati Uniti
-
Erasmus Medical CenterNon ancora reclutamentoInfezioni da HIV | HIV | Infezione da HIV-1 | Infezione da HIV IOlanda
-
Helios SaludViiV HealthcareSconosciutoHIV | Infezione da HIV-1Argentina
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement; Centre Pasteur du Cameroun e altri collaboratoriSconosciutoHIV | Bambini non infetti da HIV | Bambini esposti all'HIVCamerun
-
University of MinnesotaCompletatoInfezioni da HIV | HIV | ImmunodeficienzaStati Uniti
-
Midway Specialty Care CenterNon ancora reclutamentoInfezioni da HIV | HIV | Infezione da HIV-1Stati Uniti
-
Allegheny Singer Research Institute (also known...Attivo, non reclutanteInfezioni da HIV | Infezione da HIV-1 | Infezione da HIV IStati Uniti
-
University of California, DavisCompletato
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completato
-
University of ZimbabweCompletato
Prove cliniche su ARV treatment
-
PfizerArvinas Estrogen Receptor, Inc.Completato
-
Arvinas Androgen Receptor, Inc.Attivo, non reclutanteCancro alla prostata metastaticoStati Uniti
-
PfizerArvinas Estrogen Receptor, Inc.Attivo, non reclutante
-
Arvinas Inc.ReclutamentoLinfoma non Hodgkin (NHL) a cellule B mature recidivante/refrattario (R/R) | Linfoma angioimmunoblastico a cellule T (AITL) recidivante/refrattario (R/R)Stati Uniti, Spagna
-
PfizerArvinas Estrogen Receptor, Inc.Attivo, non reclutante
-
Arvinas Androgen Receptor, Inc.Reclutamento
-
Hill-RomCompletato
-
Reistone Biopharma Company LimitedCompletato
-
Ohio State UniversityReclutamentoGenitorialità | Disturbi mentali nell'adolescenza | Adolescente - Problema emotivoStati Uniti
-
National Institute on Aging (NIA)SconosciutoDemenza | Problemi di comportamentoStati Uniti